Skip to main content

Drug Interactions between Erivedge and Mylanta Ultra

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

calcium carbonate vismodegib

Applies to: Mylanta Ultra (calcium carbonate / magnesium hydroxide) and Erivedge (vismodegib)

The solubility of vismodegib is known to be pH-dependent (0.1 mcg/mL at pH 7 and 0.99 mg/mL at pH 1) and drugs that alter the pH of the upper gastrointestinal tract may affects its solubility and reduce its bioavailability. However, a clinically significant pharmacokinetic effect has not been observed, with results from a clinical study showing a 33% reduction in the unbound drug concentrations of vismodegib after 7 days of concomitant therapy with the proton pump inhibitor rabeprazole (20 mg, given 2 hours before each vismodegib administration).

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Erivedge (vismodegib)." Genentech (2012):

Switch to consumer interaction data

Minor

magnesium hydroxide vismodegib

Applies to: Mylanta Ultra (calcium carbonate / magnesium hydroxide) and Erivedge (vismodegib)

The solubility of vismodegib is known to be pH-dependent (0.1 mcg/mL at pH 7 and 0.99 mg/mL at pH 1) and drugs that alter the pH of the upper gastrointestinal tract may affects its solubility and reduce its bioavailability. However, a clinically significant pharmacokinetic effect has not been observed, with results from a clinical study showing a 33% reduction in the unbound drug concentrations of vismodegib after 7 days of concomitant therapy with the proton pump inhibitor rabeprazole (20 mg, given 2 hours before each vismodegib administration).

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Erivedge (vismodegib)." Genentech (2012):

Switch to consumer interaction data

Drug and food interactions

Moderate

calcium carbonate food

Applies to: Mylanta Ultra (calcium carbonate / magnesium hydroxide)

ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.

MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
  5. Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
  6. Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
View all 6 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer